Genmab drops 2 antibody assets, including another ProfoundBio ADC
BioSpace
Rina-S is the last candidate standing from Genmab's $1.8 billion ProfoundBio acquisition two years ago, with the Danish drugmaker ending development of another clinical program stemming from the buyou
Rina-S is the last candidate standing from Genmab’s $1.8 billion ProfoundBio acquisition two years ago, with the Danish drugmaker ending development of another clinical program stemming from the buyou
